6-phosphogluconate dehydrogenase deficiency

6-Phosphogluconate dehydrogenase deficiency
Synonyms	6PGD deficiency
Pronounce	N/A
Specialty	N/A
Symptoms	Hemolytic anemia, jaundice, fatigue
Complications	Chronic hemolytic anemia
Onset	Varies
Duration	Lifelong
Types	N/A
Causes	Genetic mutation in the 6-phosphogluconate dehydrogenase gene
Risks	Family history
Diagnosis	Blood test, genetic testing
Differential diagnosis	Glucose-6-phosphate dehydrogenase deficiency, Pyruvate kinase deficiency
Prevention	None
Treatment	Avoidance of triggers, blood transfusion
Medication	None specific
Prognosis	Variable, generally good with management
Frequency	Rare
Deaths	N/A

6-Phosphogluconate dehydrogenase deficiency is a rare metabolic disorder that affects the pentose phosphate pathway, specifically the oxidative phase. This deficiency is due to a lack of the enzyme 6-phosphogluconate dehydrogenase, which plays a crucial role in the conversion of 6-phosphogluconate to ribulose 5-phosphate.

Pathophysiology

The pentose phosphate pathway is essential for the production of NADPH and ribose 5-phosphate. NADPH is crucial for biosynthetic reactions and for maintaining the redox state of cells by regenerating glutathione. In 6-phosphogluconate dehydrogenase deficiency, the reduced activity of the enzyme leads to decreased NADPH production, which can impair the cell's ability to handle oxidative stress.

Clinical Manifestations

Individuals with 6-phosphogluconate dehydrogenase deficiency may present with symptoms similar to those seen in other red blood cell enzymopathies, such as hemolytic anemia. Symptoms can include fatigue, jaundice, and pallor. The severity of symptoms can vary widely among affected individuals.

Diagnosis

Diagnosis of 6-phosphogluconate dehydrogenase deficiency is typically made through biochemical assays that measure the activity of the enzyme in red blood cells. Genetic testing can also be used to identify mutations in the gene encoding 6-phosphogluconate dehydrogenase.

Treatment

There is no specific treatment for 6-phosphogluconate dehydrogenase deficiency. Management focuses on avoiding triggers of hemolysis, such as certain drugs and infections. In cases of severe anemia, blood transfusions may be necessary.

Related pages

• Pentose phosphate pathway
• NADPH
• Hemolytic anemia
• Enzyme deficiency

This article is a stub related to genetics. You can help WikiMD by expanding it!